[en] Aminosalicylates (5-ASA, sulfasalazine and mesalazine) play a central role in the treatment of ulcerative colitis (UC). For acute treatment of mild to moderate flares and in maintenance treatment, their efficacy has been established. Since ulcerative colitis is limited to the distal colon in two thirds of the patients, topical therapy also plays an important role. In mild/moderate active disease 5-ASA 4 g/d is as effective as oral corticosteroids. Ulcerative proctitis is treated with 2 x 500 mg or 1 x 1 g suppositories and proctosigmoiditis with 1 to 4 g enemas. Oral 5-ASA is also safe in maintenance treatment and is generally well tolerated. The risk of colorectal tumours is increased in patients with longstanding ulcerative colitis and epidemiological evidence indicates that chronic 5-ASA treatment reduces this risk. However, at present there is insufficient evidence to maintain patients on life-long 5-ASA maintenance treatment for this indication.
Disciplines :
Gastroenterology & hepatology
Author, co-author :
Van Assche, Gert
Baert, Filip
De Reuck, Marc
Devos, Martine ; Centre Hospitalier Universitaire de Liège - CHU > Centre d'oncologie
De Wit, Olivier
Hoang, Pierre
Louis, Edouard ; Université de Liège - ULiège > Département des sciences cliniques > Hépato-gastroentérologie - Relations académiques et scientifiques (Médecine)
Mana, Fazia
Pelckmans, Paul
Rutgeerts, Paul
Van Gossum, Andre
D'Haens, Geert
Language :
English
Title :
The role of aminosalicylates in the treatment of ulcerative colitis.
SUTHERLAND L.R., MAY G.R., SHAFFER E.A. Sulfasalazine revisited: a meta-analysis of 5-aminosalicylic acid in the treatment of ulcerative colitis. Ann. Intern. Med., 1993, 118: 540-549.
MINER P., NOSTRANT T., WRUBLE L., HINES C., JOHNSON S., WILKINSON C., HOOP R. Multicenter trial of Pentasa for active ulcerative colitis. Gastroenterology, 1991, 100: A231.
RUTGEERTS P. Medical therapy of inflammatory bowel disease. Digestion, 1998, 59: 453-469.
JEWELL D.P., CAPRILLI R., MORTENSEN N., NICHOLLS R.J., WRIGHT J.P. Indication and timing of surgery for severe ulcerative colitis. Gastroenterol. International, 1991, 4: 161-164.
BROWN J., HAINES S., WILDING I.R. Colonic spread of three rectally administered mesalazine (Pentasa) dosage forms in healthy volunteers as assessed by gamma scintigraphy. Aliment Pharmacol. Ther., 1997, 11: 685-691.
SUTHERLAND L.R. Topical treatment of ulcerative colitis. Med. Clin. N. Am., 1990, 74: 119-131.
HANNAUER S.B. Dose-ranging study of mesalamine enemas in the treatment of acute ulcerative proctosigmoiditis: results of a multicentered placebo-controlled trial. Inflam. Bowel Dis., 1998, 4: 79-83.
CAMPIERI M., GIONCHETTI P., BELLUZZI A., BRIGNOLA C., TAMPIERI M., IANNONE P., MIGLIOLI M., BARBARA L. Optimum dosage of 5-aminosalicylic acid as rectal enemas in patients with active UC. Gut, 1991, 32: 929-931.
GIONCHETTI P., RIZZELLO F., VENTURI A., BRIGNOLA C., FERRETTI M., PERUZZO S., CAMPIERI M. Comparison of mesalazine suppositories in proctitis and distal proctosigmoiditis. Aliment Pharmacol. Therap., 1997, 11: 1053-1057.
MARTEAU P., NELET F., LE LU M., DEVAUX C. Adverse events in patients treated with 5-aminosalicylic acid: 1993-1994 pharmacovigilance report for Pentasa in France. Aliment Pharmacol. Ther., 1996, 10: 949-956.
ARDIZZONE S., PETRILLO M., IMBESI V., CERUTTI R., BOLLANI S., BIANCHI-PORRO G. Is maintenance therapy always necessary for patients with ulcerative colitis in remission? Aliment Pharmacol. Ther., 1999, 13: 373-379.
EADEN J., ABRAMS K., EKBOM A., JACKSON E., MAYBERR J. Colorectal cancer prevention in ulcerative colitis: a case control study. Aliment Pharmacol. Ther., 2000, 14: 145-153.
